ROS1重排、MET扩增的肺腺癌在恩替雷尼耐药后对克唑替尼的反应

IF 5.3 2区 医学 Q1 ONCOLOGY
JCO precision oncology Pub Date : 2024-10-01 Epub Date: 2024-10-07 DOI:10.1200/PO-24-00394
Victor R Vaz, Malini M Gandhi, Biagio Ricciuti, Joao V Alessi, Arielle Elkrief, Marc Ladanyi, Chad Vanderbilt, Federica Pecci, Mihaela Aldea, Adriana Barrichello, Arushi Saini, Lynette Sholl, Jacob M Sands, Mark M Awad
{"title":"ROS1重排、MET扩增的肺腺癌在恩替雷尼耐药后对克唑替尼的反应","authors":"Victor R Vaz, Malini M Gandhi, Biagio Ricciuti, Joao V Alessi, Arielle Elkrief, Marc Ladanyi, Chad Vanderbilt, Federica Pecci, Mihaela Aldea, Adriana Barrichello, Arushi Saini, Lynette Sholl, Jacob M Sands, Mark M Awad","doi":"10.1200/PO-24-00394","DOIUrl":null,"url":null,"abstract":"<p><p>Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"8 ","pages":"e2400394"},"PeriodicalIF":5.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung Adenocarcinoma.\",\"authors\":\"Victor R Vaz, Malini M Gandhi, Biagio Ricciuti, Joao V Alessi, Arielle Elkrief, Marc Ladanyi, Chad Vanderbilt, Federica Pecci, Mihaela Aldea, Adriana Barrichello, Arushi Saini, Lynette Sholl, Jacob M Sands, Mark M Awad\",\"doi\":\"10.1200/PO-24-00394\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.</p>\",\"PeriodicalId\":14797,\"journal\":{\"name\":\"JCO precision oncology\",\"volume\":\"8 \",\"pages\":\"e2400394\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO precision oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/PO-24-00394\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO-24-00394","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

克唑替尼成功克服了恩替利尼失败后ROS1重排NSCLC中的MET扩增。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma.

Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.10
自引率
4.30%
发文量
363
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信